• Agios Pharmaceuticals recently reported that, following a pre-supplemental New Drug Application meeting, the FDA encouraged it to seek U.S. accelerated approval of mitapivat for sickle cell disease and submit a confirmatory trial proposal based on the RISE UP Phase 2 and 3 data package.
• The move to accelerated approval, with a new confirmatory trial endpoint and operating expenses expected to remain roughly flat versus 2025, could reshape how investors view Agios’s risk–reward profile around mitapivat in sickle cell disease.
• We’ll now examine how the FDA’s openness to an accelerated mitapivat pathway may influence Agios’s rare-disease-focused investment narrative.

Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

Agios Pharmaceuticals Investment Narrative Recap

To own Agios today, you have to believe in mitapivat as a cornerstone rare‑disease franchise and in management’s ability to convert clinical validation into durable revenues despite ongoing losses. The FDA’s encouragement to pursue accelerated approval for mitapivat in sickle cell disease makes that program an even clearer near term catalyst, while the biggest current risk remains the company’s dependence on a single platform and continued heavy spending without a clear path to profitability.

Among recent announcements, the planned April 29, 2026 first quarter earnings call stands out, as it will give investors an updated view on how Agios is funding the new confirmatory mitapivat trial and managing expenses that are expected to stay roughly flat versus 2025, both of which matter for how the accelerated sickle cell pathway could affect the timing and scale of any future revenue inflection.

Yet investors should still weigh how Agios’s concentrated pipeline risk could affect them if mitapivat’s sickle cell trajectory does not...

Agios Pharmaceuticals' narrative projects $371.8 million revenue and $54.9 million earnings by 2029. This requires 90.2% yearly revenue growth and an earnings increase of about $467.7 million from -$412.8 million today.

Uncover how Agios Pharmaceuticals' forecasts yield a $41.50 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were once modeling revenue to climb toward about US$465.1 million by 2028, yet the same reliance on a narrow PYRUKYND and mitapivat portfolio they flagged as a key vulnerability could look very different in light of the FDA’s openness to an accelerated sickle cell pathway, which is why it is worth comparing these more bullish expectations with your own view of the risks.

Explore 2 other fair value estimates on Agios Pharmaceuticals - why the stock might be worth over 6x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Agios Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agios Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.